Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 161-179

  Gacche, Rajesh N ^a   Meshram, Rohan J ^a  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

Author keywords

Anti angiogenic therapy; Pro angiogenic cytokines; Tumor angiogenesis

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GROWTH FACTOR; NEUROPILIN 1; NEUROPILIN 2; PANITUMUMAB; PAZOPANIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; REGORAFENIB; SCATTER FACTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC THERAPY; BINDING AFFINITY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL ADHESION; CELL COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION;

ANTI-ANGIOGENIC THERAPY; PRO-ANGIOGENIC CYTOKINES; TUMOR ANGIOGENESIS;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CELL PROLIFERATION; GENES, SWITCH; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 84901630184     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.05.002     Document Type: Review

References (322)

1. Abounader R., Lal B., Luddy C., Koe G., Davidson B., Rosen E.M., Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002, 16:108-110.
2. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 2005, 7:436-451.
3. Abounader R., Montgomery R., Dietz H., Laterra J. Design and expression of chimeric U1/ribozyme transgenes. Methods Mol. Biol. 2004, 252:209-219.
4. Adini A., Kornaga T., Firoozbakht F., Benjamin L.E. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 2002, 62:2749-2752.
5. Ahmed A., Dunk C., Ahmad S., Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta 2000, 21:S16-S24.
6. Alan F.L. Vascular endothelial growth factor signalling pathway as an emerging target in hematologic malignancies. Oncologist 2001, 6:24-31.
7. Alexandrakis M.G., Passam F.J., Ganotakis E., Dafnis E., Dambaki C., Konsolas J., Kyriakou D.S., Stathopoulos E. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin. Chem. Lab. Med. 2004, 42:1122-1126.
8. Allt G., Lawrenson J.G. Pericytes: cell biology and pathology. Cells Tissues Organs 2001, 169:1-11.
9. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
10. Amini A., Masoumi Moghaddam S., Morris D.L., Pourgholami M.H. Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J. Oncol. 2012, 540-791. (2012).
11. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
12. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
13. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
14. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 2003, 9:936-943.
15. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001, 61:5736-5740.
16. Baffert F., Thurston G., Rochon-Duck M., Le T., Brekken R., McDonald D.M. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ. Res. 2004, 94:984-992.
17. Bagnato A., Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol. Metab. 2003, 14:44-50.
18. Bainbridge J.W., Mistry A.R., Thrasher A.J., Ali R.R. Gene therapy for ocular angiogenesis. Clin. Sci. (Lond.) 2003, 104:561-575.
19. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Kolumam G., Vernes J.M., Eastham-Anderson J., Haughney P., Kowanetz M., Hagenbeek T., Kasman I., Reslan H.B., Ross J., Van Bruggen N., Carano R.A., Meng Y.J., Hongo J.A., Stephan J.P., Shibuya M., Ferrara N. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
20. Banerjee D., Harfouche R., Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vasc. Cell 2011, 3:3.
21. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
22. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
23. Bear H.D., Tang G., Rastogi P., Geyer C.E., Robidoux A., Atkins J.N., Baez-Diaz L., Brufsky A.M., Mehta R.S., Fehrenbacher L., Young J.A., Senecal F.M., Gaur R., Margolese R.G., Adams P.T., Gross H.M., Costantino J.P., Swain S.M., Mamounas E.P., Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 2012, 366:310-320.
24. Beeghly-Fadiel A., Shu X.O., Lu W., Long J., Cai Q., Xiang Y.B., Zheng Y., Zhao Z., Gu K., Gao Y.T., Zheng W. Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol. Biomarkers Prev. 2011, 20:33-41.
25. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
26. Bellik L., Vinci M.C., Filippi S., Ledda F., Parenti A. Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. Br. J. Pharmacol. 2005, 146:568-575.
27. Benest A.V., Salmon A.H., Wang W., Glover C.P., Uney J. VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation 2006, 13:423-437.
28. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
29. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
30. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
31. Bergsten E., Uutela M., Li X., Pietras K., Ostman A., Heldin C.H., Alitalo K., Eriksson U. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 2001, 3:512-516.
32. 2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
33. Betsholtz C., Lindblom P., Gerhardt H. Role of pericytes in vascular morphogenesis. EXS 2005, 94:115-125.
34. Bjorndahl M., Cao R., Eriksson A., Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ. Res. 2004, 94:1443-1450.
35. Brave S.R., Eberlein C., Shibuya M., Wedge S.R., Barry S.T. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010, 13:337-347.
36. Brown J.L., Cao Z.A., Pinzon-Ortiz M., Kendrew J., Reimer C., Wen S., Zhou J.Q., Tabrizi M., Emery S., McDermott B., Pablo L., McCoon P., Bedian V., Blakey D.C. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010, 9:145-156.
37. Brunckhorst M.K., Wang H., Lu R., Yu Q. Enhancing tumor cell viability and angiogenesis angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res. 2010, 70:7283-7293.
38. Burstein H.J., Chen Y.H., Parker L.M., Savoie J., Younger J., Kuter I., Ryan P.D., Garber J.E., Chen H., Campos S.M., Shulman L.N., Harris L.N., Gelman R., Winer E.P. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 2008, 14:7871-7877.
39. Cai J., Jiang W.G., Grant M.B., Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J. Biol. Chem. 2006, 281:3604-3613.
40. Cai M., Zhang H., Hui R. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem. Biophys. Res. Commun. 2003, 309:946-951.
41. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7443-7448.
42. Cao Y., Cao R., Hedlund E.M. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. 2008, 86:785-789.
43. Cao Y., Guangqi E., Wang E., Pal K., Dutta S.K., Bar-Sagi D., Mukhopadhyay D. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012, 72:3912-3918.
44. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2. (re1).
45. Carlson T.R., Feng Y., Maisonpierre P.C., Mrksich M., Morla A.O. Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 2001, 276:26516-26525.
46. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
47. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
48. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., VandenDriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
49. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
50. Carpini J.D., Karam A.K., Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010, 13:43-58.
51. Cascone T., Heymach J.V. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J. Clin. Oncol. 2012, 30:441-444.
52. Cathcart M.C., Gately K., Cummins R., Drakeford C., Kay W.E., O'Byrne K.J., Pidgeon G.P. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochim. Biophys. Acta 2014, (1842):747-755.
53. Cervi D., Shaked Y., Haeri M., Usenko T., Lee C.R., Haigh J.J., Nagy A., Kerbel R.S., Yefenof E., Ben-David Y. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 2007, 109:2139-2146.
54. Chakroborty D., Sarkar C., Basu B., Dasgupta P.S., Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009, 69:3727-3730.
55. Chakroborty D., Sarkar C., Mitra R.B., Banerjee S., Dasgupta P.S., Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 2004, 10:4349-4356.
56. Chang S.H., Kanasaki K., Gocheva V., Blum G., Harper J., Moses M.A., Shih S.C., Nagy J.A., Joyce J., Bogyo M., Kalluri R., Dvorak H.F. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009, 69:4537-4544.
57. Chaudhuri P., Harfouche R., Soni S., Hentschel D.M., Sengupta S. Shape effect of carbon nanovectors on angiogenesis. ACS Nano 2010, 4:574-582.
58. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Enhanced hepatocyte growth factor signalling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 2007, 67:4869-4877.
59. Christinger H.W., Fuh G., de Vos A.M., Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 2004, 279:10382-10388.
60. Christophi C., Harun N., Fifis T. Liver regeneration and tumor stimulation-A review of cytokine and angiogenic factors. J. Gastrointest. Surg. 2008, 12:966-980.
61. Chu S.H., Ma Y.B., Zhang H., Feng D.F., Zhu Z.A., Li Z.Q., Yuan X.H. Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J. Neurooncol. 2007, 85:33-38.
62. Cianfarani F., Zambruno G., Brogelli L., Sera F., Lacal P.M., Pesce M., Capogrossi M.C., Failla C.M., Napolitano M., Odorisio T. Placenta growth factor in diabetic wound healing altered expression and therapeutic potential. Am. J. Pathol. 2006, 169:1167-1182.
63. Clarke J.M., Hurwitz H.I. Understanding and targeting resistance to anti-angiogenic therapies. J. Gastrointest. Oncol. 2013, 4:253-263.
64. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M., Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60:7163-7169.
65. Conklin L.D., McAninch R.E., Schulz D., Kaluza G.L., LeMaire S.A., Coselli J.S., Raizner A.E., Sutton R.E. HIV-based vectors and angiogenesis following rabbit hind limb ischemia. J. Surg. Res. 2005, 123:55-66.
66. Creamer D., Sullivan D., Bicknell R., Barker J. Angiogenesis in psoriasis. Angiogenesis 2002, 5:231-236.
67. Croci D.O., Cerliani J.P., Dalotto-Moreno T., Méndez-Huergo S.P., Mascanfroni I.D., Dergan-Dylon S., Toscano M.A., Caramelo J.J., García-Vallejo J.J., Ouyang J., Mesri E.A., Junttila M.R., Bais C., Shipp M.A., Salatino M., Rabinovich G.A. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014, 13(4):744-758.
68. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
69. Daly C., Pasnikowski E., Burova E., Wong V., Aldrich T.H., Griffiths J., Ioffe E., Daly T.J., Fandl J.P., Papadopoulos N., McDonald D.M., Thurston G., Yancopoulos G.D., Rudge J.S. Angiopietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15491-15496.
70. Das S., Ladell D.S., Podgrabinska S., Ponomarev V., Nagi C., Fallon J.T., Skobe M. Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res. 2010, 70:1814-1824.
71. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
72. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
73. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21:73-79.
74. De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012, 44:1-9.
75. De Palma M., Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res. 2011, 17:5226-5232.
76. Decaris M.L., Lee C.I., Yoder M.C., Tarantal A.F., Leach J.K. Influence of the oxygen microenvironment on the proangiogenic potential of human endothelial colony forming cells. Angiogenesis 2009, 12:303-311.
77. Del Toro R., Prahst C., Mathivet T., Siegfried G., Kaminker J.S., Larrivee B., Breant C., Duarte A., Takakura N., Fukamizu A., Penninger J., Eichmann A. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010, 116:4025-4033.
78. Dell'Era P., Belleri M., Stabile H., Massardi M.L., Ribatti D., Presta M. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001, 20:2655-2663.
79. Depoix C., Tee M.K., Taylor R.N. Molecular regulation of human placental growth factor (PlGF) gene expression in placental villi and trophoblast cells is mediated via the protein kinase A pathway. Reprod. Sci. 2011, 18:219-228.
80. Dewerchin M., Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect. Med. 2012, 2:(a011056).
81. Ding S., Merkulova-Rainon T., Han Z.C., Tobelem G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101:4816-4822.
82. Du H., Li P., Pan Y., Li W., Hou J., Chen H., Wang J., Tang H. Vascular endothelial growth factor signaling implicated in neuroprotective effects of placental growth factor in an in vitro ischemic model. Brain Res. 2010, 1357:1-8.
83. Dvorak P., Dvorakova D., Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett. 2006, 580:2869-2874.
84. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
85. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
86. Enge M., Bjarnegård M., Gerhardt H., Gustafsson E., Kalén M., Asker N., Hammes H.P., Shani M., Fässler R., Betsholtz C. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002, 21:4307-4316.
87. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18:338-340.
88. Eriksson A., Cao R., Pawliuk R., Berg S.M., Tsang M., Zhou D., Fleet C., Tritsaris K., Dissing S., Leboulch P., Cao Y. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2003, 1:99-108.
89. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
90. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001, 61:2145-2153.
91. Fagiani E., Lorentz P., Kopfstein L., Christofori G. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res. 2011, 71:5717-5727.
92. Falcon B.L., Pietras K., Chou J., Chen D., Sennino B., Hanahan D., McDonald D.M. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am. J. Pathol. 2011, 178(6):2920-2930.
93. Falcón B.L., Hashizume H., Koumoutsakos P., Chou J., Bready J.V., Coxon A., Oliner J.D., McDonald D.M. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 2009, 175:2159-2170.
94. Fan F., Schimming A., Jaeger D., Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J. Oncol. 2012, 2012:281261. 10.1155/2012/281261.
95. Felcht M., Luck R., Schering A., Seidel P., Srivastava K., Hu J., Bartol A., Kienast Y., Vettel C., Loos E.K., Kutschera S., Bartels S., Appak S., Besemfelder E., Terhardt D., Chavakis E., Wieland T., Klein C., Thomas M., Uemura A., Goerdt S., Augustin H.G. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signalling. J. Clin. Invest. 2012, 122:1991-2005.
96. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 1999, 5:1359-1364.
97. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
98. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
99. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161:851-858.
100. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
101. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010, 21:21-26.
102. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 94:209-231.
103. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
104. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
105. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
106. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
107. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
108. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
109. Fountzilas G., Kourea H.P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., Papazisis K.T., Timotheadou E., Efstratiou I., Koutras A., Pentheroudakis G., Christodoulou C., Aravantinos G., Miliaras D., Petraki K., Papandreou C.N., Papakostas P., Bafaloukos D., Repana D., Razis E., Pectasides D., Dimopoulos A.M. Paclitaxel and Bevacizumab as first line combined treatment in patients with metastatic breast cancer, the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res. 2011, 31:3007-3018.
110. Frederiksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
111. Frleta M., van Baarsen L.G.M., Garcia-Perez S., de Launay D., Garrelfs M., Gerlag D.M., Tak P.P., Reedquist K.A. Differential expression of transcription factors predicted to regulate angiopoietin-1 and -2 genes is associated with specific angiopoietin signatures in RA and PsA synovial tissue. Pediatr. Rheumatol. 2011, 9:P278.
112. Frontini M.J., Nong Z., Gros R., Drangova M., O'Neil C., Rahman M.N., Akawi O., Yin H., Ellis C.G., Pickering J.G. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat. Biotechnol. 2011, 29:421-427.
113. Gacche R.N., Meshram R.J. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog. Biophys. Mol. Biol. 2013, 10.1016/j.pbiomolbio.2013.10.001.
114. Gacche R.N., Shegokar H.D., Gond D.S., Jadhav A.D., Ghole V.S. Effect of hydroxyl substitution of flavone on antiangiogenic and free radical scavenging activities: a structure activity relationship studies using computational tools. Eur. J. Pharm. Sci. 2010, 39:37-44.
115. Gacche R.N., Shegokar H.D., Gond D.S., Zhenzhou Y., Jadhav A.D. Evaluation of selected flavonoids as antiangiogenic, anticancer and radical scavenging agents, an experimental and in silico analysis. Cell Biochem. Biophys. 2011, 61:651-663.
116. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
117. Gavard J. Breaking the VE-cadherin bonds. FEBS Lett. 2009, 583:1-6.
118. Gerber P.A., Hippe A., Buhren B.A., Muller A., Homey B. Chemokines in tumor-associated angiogenesis. Biol. Chem. 2009, 390:1213-1223.
119. Geretti E., Shimizu A., Kurschat P., Klagsbrun M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. J. Biol. Chem. 2002, 282:25698-25707.
120. Geretti E., van Meeteren L.A., Shimizu A., Dudley A.C., Claesson-Welsh L., Klagsbrun M. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Mol. Cancer Res. 2010, 8:1063-1073.
121. Gigante B., Tarsitano M., Cimini V., De Falco S., Persico M.G. Placenta growth factor is not required for exercise-induced angiogenesis. Angiogenesis 2004, 7:277-284.
122. Gilert A., Machluf M. Nano to micro delivery systems: targeting angiogenesis in brain tumors. J. Angiogenes. Res. 2010, 2:20. (check out page numbers, sir mentioned it to be 1-11, but pubmed says its 20).
123. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
124. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
125. Greenblatt M., Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparant chamber technique. J. Natl. Cancer Inst. 1968, 41:111-124.
126. Griffioen A., Mans L.A., de Graaf A.M.A., Nowak-Sliwinska Patrycja, de Hoog Celine L.M.M., de Jong Trees A.M., Vyth-Dreese Florry A., van Beijnum Judy R., Bex Axel, Jonasc Eric Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 2012, 18:3961-3971.
127. Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signalling. Biochim. Biophys. Acta 2010, 1804:567-580.
128. Gupta K., Zhang J. Angiogenesis: a curse or cure?. Postgrad. Med. J. 2005, 81:236-242.
129. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
130. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
131. Harfouche R., Basu S., Soni S., Hentschel D.M., Mashelkar R.A., Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009, 12:325-338.
132. Hashizume H., Falcón B.L., Kuroda T., Baluk P., Coxon A., Yu D., Bready J.V., Oliner J.D., McDonald D.M. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010, 70:2213-2223.
133. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D.J., Zhu Z., Bohlen P., Witte L., Hendrikx J., Hackett N.R., Crystal R.G., Moore M.A., Werb Z., Lyden D., Rafii S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 2002, 8:841-849.
134. Hawighorst T., Skobe M., Streit M., Hong Y.K., Velasco P., Brown L.F., Riccardi L., Lange-Asschenfeldt B., Detmar M. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol. 2002, 160:1381-1392.
135. Hayes A.J., Huang W.Q., Yu J., Maisonpierre P.C., Liu A., Kern F.G., Lippman M.E., McLeskey S.W., Li L.Y. Expression and function of angiopoietin-1 in breast cancer. Br. J. Cancer 2000, 83:1154-1160.
136. He T., Qi F., Jia L., Wang S., Song N., Guo L., Fu Y., Luo Y. MicroRNA-542-3p inhibits tumour angiogenesis by targeting Angiopoietin-2. J. Pathol. 2014, 232(5):499-508.
137. Heldin C.H., Eriksson U., Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 2002, 398:284-290.
138. Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M., Kato M., Ergün S., Augustin H.G., Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 2010, 207:491-503.
139. Herrmann J., Lerman L.O., Mukhopadhyay D., Napoli C., Lerman A. Angiogenesis in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1948-1957.
140. Holopainen T., Huang H., Chen C., Kim K.E., Zhang L., Zhou F., Han W., Li C., Yu J., Wu J., Koh G.Y., Alitalo K., He Y. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res. 2009, 69:4656-4664.
141. Holopainen T., Saharinen P., D'Amico G., Lampinen A., Eklund L., Sormunen R., Anisimov A., Zarkada G., Lohela M., Heloterä H., Tammela T., Benjamin L.E., Ylä-Herttuala S., Leow C.C., Koh G.Y., Alitalo K. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 2012, 104:461-475.
142. Hoot K.E., Oka M., Han G., Bottinger E., Zhang Q., Wang X.J. HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J. Clin. Invest. 2010, 120:3606-3616.
143. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1:323-334.
144. Huang J., Bae J.O., Tsai J.P., Kadenhe-Chiweshe A., Papa J., Lee A., Zeng S., Kornfeld Z.N., Ullner P., Zaghloul N., Ioffe E., Nandor S., Burova E., Holash J., Thurston G., Rudge J., Yancopoulos G.D., Yamashiro D.J., Kandel J.J. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 2009, 34:79-87.
145. Huang Y., Gilbert P.B. Comparing biomarkers as principal surrogate endpoints. Biometrics 2011, 67:1442-1451.
146. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus Irinotecan, Flouorouracil and Leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
147. Hurwitz H.I., Douglas P.S., Middleton J.P., Sledge G.W., Johnson D.H., Reardon D.A., Chen D., Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013, 18:273-280.
148. Ichihara E., Kiura K., Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med. Okyama 2011, 65:353-362.
149. Iyer S., Darley P.I., Acharya K.R. Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity. J. Biol. Chem. 2010, 285:23779-23789.
150. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
151. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T., Sorensen A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
152. Jin Y., Jakobsson L. The dynamics of developmental and tumor angiogenesis-A comparison. Cancers 2012, 4:400-419.
153. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of Bevacizumab in cancer. Lancet Oncol. 2010, 11:1172-1183.
154. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., Kabbinavar F., Holden S.N., Novotny W.F., Frantz G.D., Hillan K.J., Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006, 24:217-227.
155. Jubb A.M., Turley H., Moeller H.C., Steers G., Han C., Li J.L., Leek R., Tan E.Y., Singh B., Mortensen N.J., Noguera-Troise I., Pezzella F., Gatter K.C., Thurston G., Fox S.B., Harris A.L. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br. J. Cancer 2009, 101:1749-1757.
156. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
157. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.
158. Kase S., He S., Sonoda S., Kitamura M., Spee C., Wawrousek E., Ryan S.J., Kannan R., Hinton D.R. alphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 2010, 115:3398-3406.
159. Kathryn J.W., Morag G.H., George E.M., Mhairi L., Amanda J.H., Robert S.R. Fibroblast growth factor 2 is a key determinant of vascular sprouting during bovine luteal angiogenesis. Reproduction 2012, 143:35-43.
160. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Klement G., Coomber B.L., Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001, 20:79-86.
161. Kerbel R.S. Tumor angiogenesis: past, present and near future. Carcinogenesis 2000, 21:505-515.
162. Kerber M., Reiss Y., Wickersheim A., Jugold M., Kiessling F., Heil M., Tchaikovski V., Waltenberger J., Shibuya M., Plate K.H., Machein M.R. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008, 68:7342-7351.
163. Khaliq A., Dunk C., Jiang J., Shams M., Li X.F., Acevedo C., Weich H., Whittle M., Ahmed A. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab. Invest. 1999, 79:151-170.
164. Kieran M.W., Kalluri R., Cho Y.-J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb. Perspect. Med. 2012, 2:a006593.
165. Kilvaer T.K., Valkov A., Sorbye S.W., Smeland E., Bremnes R.M., Busund L.T., Donnem T. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J. Transl. Med. 2011, 9:104.
166. Kim I., Kwak H.J., Ahn J.E., So J.N., Liu M., Koh K.N., Koh G.Y. Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett. 1999, 443:353-356.
167. Kim K.J., Cho C.S., Kim W.U. Role of placenta growth factor in cancer and inflammation. Exp. Mol. Med. 2012, 44:10-19.
168. Klagsbrun M., Takashima S., Mamluk R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 2002, 515:33-48.
169. Koh Y.J., Kim H.Z., Hwang S.I., Lee J.E., Oh N., Jung K., Kim M., Kim K.E., Kim H., Lim N.K., Jeon C.J., Lee G.M., Jeon B.H., Nam D.H., Sung H.K., Nagy A., Yoo O.J., Koh G.Y. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
170. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., Adinin R., Overman M.J., Valero V., Wen S., Lieu C., Yan S., Tran H.T., Ellis L.M., Abbruzzese J.L., Heymach J.V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28:453-459.
171. Kottakis F., Polytarchou C., Foltopoulou P., Sanidas I., Kampranis S.C., Tsichlis P.N. FGF-2 regulates cell proliferation, migration and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol. Cell 2011, 43:285-298.
172. Kowalczuk L., Touchard E., Omri S., Jonet L., Klein C., Valamanes F., Berdugo M., Bigey P., Massin P., Jeanny J.C., Behar-Cohen F. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS ONE 2011, 6:e17462.
173. Kubo H., Cao R., Brakenhielm E., Makinen T., Cao Y., Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8868-8873.
174. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J. Med. 2012, 61:47-56.
175. Kumar B., Chile KB Shailaja A., Ray G.E.C., Reddy V. VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway. Angiogenesis 2011, 14:371-380.
176. Kunnakkat S., Narayana A. Bevacizumab in the treatment of high-grade gliomas: an overview. Angiogenesis 2011, 14:423-430.
177. Lambrechts D., Lenz H.J., de Haas S., Carmeliet P., Scherer S.J. Markers of response for the antiangiogenic agent bevacizumab. J. Clin. Oncol. 2013, 31:1219-1230.
178. Lange S., Heger J., Euler G., Wartenberg M., Piper H.M., Sauer H. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic cell-derives endothelial cells by calcium mediated generation of reactive oxygen species. Cardiovasc. Res. 2009, 81:159-168.
179. Lederle W., Linde N., Heusel J., Bzyl J., Woenne E.C., Zwick S., Skobe M., Kiessling F., Fusenig N.E., Mueller M.M. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am. J. Pathol. 2010, 176:981-994.
180. Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y., Kim J.H., Oh J.L., Lee G.M., Koh G.Y. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J. 2004, 18:1200-1208.
181. Lewis M.P., Lygoe K.A., Nystrom M.L., Anderson W.P., Speight P.M., Marshall J.F., Thomas G.J. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 2004, 90:822-832.
182. Ley C.D., Olsen M.W., Lund E.L., Kristjansen P.E. Angiogenic synergy of bFGF and VEGF is antagonized by angiopoietin-2 in a modified in vivo Matrigel assay. Microvasc. Res. 2004, 68:161-168.
183. Li B., Sharpe E.E., Maupin A.B., Teleron A.A., Pyle A.L., Carmeliet P., Young P.P. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006, 20:1495-1497.
184. Li H., Fredriksson L., Li X., Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003, 22:1501-1510.
185. Li W.W., Li V.W., Hutnik M., Chiou A.S. Tumor angiogenesis as a target for dietary cancer prevention. J. Oncol. 2012, 2012:879623. 10.1155/2012/879623.
186. Li X., Pontén A., Aase K., Karlsson L., Abramsson A., Uutela M., Bäckström G., Hellström M., Boström H., Li H., Soriano P., Betsholtz C., Heldin C.H., Alitalo K., Ostman A., Eriksson U. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2000, 2:302-309.
187. Liang H., Zhong Y., Luo Z., Huang Y., Lin H., Zhan S., Xie K., Li Q.Q. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer, an immunohistochemical study. Anticancer Res. 2011, 31:3433-3440.
188. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001, 61:253-270.
189. Lieu C., Heymach J., Overman M., Tran H., Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 2011, 17:6130-6139.
190. Liu W., Parikh A.A., Stoeltzing O., Fan F., McCarty M.F., Wey J., Hicklin D.J., Ellis L.M. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Cytokine 2005, 32:206-212.
191. Liu Y., Michalopoulos G.K., Zarnegar R. Structural and functional characterization of the mouse hepatocyte growth factor gene promoter. J. Biol. Chem. 1994, 269:4152-4160.
192. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., Armaiz-Pena G.N., Hu W., Stone R.L., Munkarah A., Ravoori M.K., Shahzad M.M., Lee J.W., Mora E., Langley R.R., Carroll A.R., Matsuo K., Spannuth W.A., Schmandt R., Jennings N.B., Goodman B.W., Jaffe R.B., Nick A.M., Kim H.S., Guven E.O., Chen Y.H., Li L.Y., Hsu M.C., Coleman R.L., Calin G.A., Denkbas E.B., Lim J.Y., Lee J.S., Kundra V., Birrer M.J., Hung M.C., Lopez-Berestein G., Sood A.K. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18:185-197.
193. Luttun A., Brusselmans K., Fukao H., Tjwa M., Ueshima S., Herbert J.M., Matsuo O., Collen D., Carmeliet P., Moons L. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun. 2002, 295:428-434.
194. Lyons J., Anthony C.T., Woltering E.A. The role of angiogenesis in neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 2010, 39:839-852.
195. Maglione D., Guerriero V., Viglietto G., Ferraro M.G., Aprelikova O., Alitalo K., Del Vecchio S., Lei K.J., Chou J.Y., Persico M.G. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993, 8:925-931.
196. Magnusson P.U., Looman C., Ahgren A., Wu Y., Claesson-Welsh L., Heuchel R.L. Platelet derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2142-2149.
197. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
198. Malamitsi-Puchner A., Boutsikou T., Economou E. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediat. Inflamm. 2005, 5:293-297.
199. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J. Biol. Chem. 2002, 277:24818-24825.
200. Marcellini M., De Luca N., Riccioni T., Ciucci A., Orecchia A., Lacal P.M., Ruffini F., Pesce M., Cianfarani F., Zambruno G., Orlandi A., Failla C.M. Increased melanoma growth and metastasis spreading in mice over expressing placenta growth factor. Am. J. Pathol. 2006, 169:643-654.
201. Martinsson-Niskanen T., Riisbro R., Larsson L., Winstedt L., Stenberg Y., Pakola S., Stassen J.M., Glazer S. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin. Ther. 2011, 33:1142-1149.
202. Mazzieri R., Pucci F., Moi D., Zonari E., Ranghetti A., Berti A., Politi L.S., Gentner B., Brown J.L., Naldini L., De Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
203. Meadows H.I., Hurwitz K.L. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2012, 2. pii: a006577.
204. Miao H.Q., Soker S., Feiner L., Alonso J.L., Raper J.A., Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphoring III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 1999, 146:233-242.
205. Michael A., Relph K., Pandha H. Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. Int. J. Cancer 2010, 127:1251-1258.
206. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6:61-73.
207. Miles D., Harbeck N., Escudier B., Hurwitz H., Saltz L., Van Cutsem E., Cassidy J., Mueller B., Sirzén F. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 2010, 29:83-88.
208. Mishra A., Verma M. Cancer biomarkers: are we ready for the prime time?. Cancers (Basel) 2010, 2:190-208.
209. Mohyeldin A., Garzón-Muvdi T., Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
210. Muramatsu M., Yamamoto S., Osawa T., Shibuya M. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 2010, 70:8211-8221.
211. Nagy J.A., Dvorak A.M., Dvorak H.F. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb. Perspect. Med. 2012, 4:a006544.
212. Nasarre P., Thomas M., Kruse K., Helfrich I., Wolter V., Deppermann C., Schadendorf D., Thurston G., Fiedler U., Augustin H.G. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009, 69:1324-1333.
213. Neufeld G., Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev. 2006, 25:373-385.
214. Nie L., Guo X., Esmailzadeh L., Zhang J., Asadi A., Collinge M., Li X., Kim J.D., Woolls M., Jin S.W., Dubrac A., Eichmann A., Simons M., Bender J.R., Sadeghi M.M. Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. J. Clin. Invest. 2013, 123:5082-5097.
215. Nissen L.J., Cao R., Hedlund E.M., Wang Z., Zhao X., Wetterskog D., Funa K., Brakenhielm E., Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117:2766-2777.
216. Nussenbaum F., Herman I.M. Tumor angiogenesis: insights and innovations. J. Oncol. 2010, 2010:132641.
217. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005, 65:3967-3979.
218. Odorisio T., Schietroma C., Zaccaria M.L., Cianfarani F., Tiveron C., Tatangelo L., Failla C.M., Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularisation and vessel permeability. J. Cell Sci. 2002, 115:2559-2567.
219. Oklu R., Walker T.G., Wicky S., Hesketh R. Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J. Vasc. Interv. Radiol. 2010, 21:1791-1805.
220. Oldenhuis C.N., Oosting S.F., Gietema J.A., de Vries E.G. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 2008, 44:946-953.
221. Oliner J., Min H., Leal J., Yu D., Rao S., You E., Tang X., Kim H., Meyer S., Han S.J., Hawkins N., Rosenfeld R., Davy E., Graham K., Jacobsen F., Stevenson S., Ho J., Chen Q., Hartmann T., Michaels M., Kelley M., Li L., Sitney K., Martin F., Sun J.R., Zhang N., Lu J., Estrada J., Kumar R., Coxon A., Kaufman S., Pretorius J., Scully S., Cattley R., Payton M., Coats S., Nguyen L., Desilva B., Ndifor A., Hayward I., Radinsky R., Boone T., Kendall R. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
222. Ori A., Wilkinson M.C., Fernig D.G. The heparanome and regulation of cell function: structures, functions and challenges. Front. Biosci. 2008, 13:4309-4338.
223. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15:275-286.
224. Oura H., Bertoncini J., Velasco P., Brown L.F., Carmeliet P., Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003, 101:560-567.
225. Paleolog E.M., Miotla J.M. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 1998, 2:295-307.
226. Pan P., Fu H., Zhang L., Huang H., Luo F., Wu W., Guo Y., Liu X. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 2010, 26:11-36.
227. Papadopoulos N., Martin J., Ruan Q., Rafique A., Rosconi M.P., Shi E., Pyles E.A., Yancopoulos G.D., Stahl N., Wiegand S.J. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012, 15:171-185.
228. Patel N., Gonsalves C.S., Malik P., Kalra V.K. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1a. Blood 2008, 112:856-865.
229. Pathak A.P., Hochfeld W.E., Goodman S.L., Pepper M.S. Circulating and imaging markers for angiogenesis. Angiogenesis 2008, 11:321-335.
230. Pecot C.V., Rupaimoole R., Yang D., Akbani R., Ivan C., Lu C., Wu S., Han H.D., Shah M.Y., Rodriguez-Aguayo C., Bottsford-Miller J., Liu Y., Kim S.B., Unruh A., Gonzalez-Villasana V., Huang L., Zand B., Moreno-Smith M., Mangala L.S., Taylor M., Dalton H.J., Sehgal V., Wen Y., Kang Y., Baggerly K.A., Lee J.S., Ram P.T., Ravoori M.K., Kundra V., Zhang X., Ali-Fehmi R., Gonzalez-Angulo A.M., Massion P.P., Calin G.A., Lopez-Berestein G., Zhang W., Sood A.K. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 2013, 4:2427. 10.1038/ncomms3427.
231. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
232. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
233. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 1992, 189:824-831.
234. Peruzzi B., Bottaro D.P. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 2006, 12:3657-3660.
235. Pipp F., Heil M., Issbrucker K. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocytemediated mechanism. Circ. Res. 2003, 92:378-385.
236. Plaschke-Schlütter A., Behrens J., Gherardi E., Birchmeier W. Characterization of the scatter factor/hepatocyte growth factor gene promoter. Positive and negative regulatory elements direct gene expression to mesenchymal cells. J. Biol. Chem. 1995, 270:830-836.
237. Polec A., Fedorcsák P., Eskild A., Tanbo T.G. The interplay of human chorionic gonadotropin (hCG) with basic fibroblast growth factor and adipokines on angiogenesis in vitro. Placenta 2014, 35:249-253.
238. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
239. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
240. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
241. Raica M., Cimpean A.M. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 2010, 3:572-599.
242. Ray A., Dhar S., Ray B.K. Cells by suppression of SAF-1 transcription factor activity control of VEGF expression in triple-negative breast carcinoma. Mol. Cancer Res. 2011, 9:1030-1041.
243. Reisinger K., Kaufmann R., Gille J. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J. Cell Sci. 2003, 116:225-238.
244. Ribatti D., Conconi M.T., Nussdorfer G.G. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol. Rev. 2007, 59:185-205.
245. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008, 11:215-221.
246. Ribattia D., Vaccab A., Prestac M. The discovery of angiogenic factors: a historical review. Gen. Pharmacol. 2000, 35:227-231.
247. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
248. Roy H., Bhardwaj S., Babu M., Jauhiainen S., Herzig K.H., Bellu A.R., Haisma H.J., Carmeliet P., Alitalo K., Ylä-Herttuala S. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum. Gene Ther. 2005, 16:1422-1428.
249. Saik J.E., Gould D.J., Watkins E.M., Dickinson M.E., West J.L. Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly (ethylene glycol) hydrogels. Acta Biomater. 2011, 7:133-143.
250. Sands M., Howell K., Costello C.M., McLoughlin P. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir. Res. 2011, 25:12-17.
251. Sarkar C., Chakroborty D., Chowdhury U.R., Dasgupta P.S., Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14:2502-2510.
252. Saucier C., Khoury H., Lai K.M., Peschard P., Dankort D., Naujokas M.A., Holash J., Yancopoulos G.D., Muller W.J., Pawson T., Park M. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2345-2350.
253. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci. 2005, 118:771-780.
254. Scholz D., Elsaesser H., Sauer A., Friedrich C., Luttun A., Carmeliet P., Schaper W. Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (PlGF) -/-mice. J. Mol. Cell. Cardiol. 2003, 35:177-184.
255. Schulz P., Fischer C., Detjen K.M., Rieke S., Hilfenhaus G., von Marschall Z., Böhmig M., Koch I., Kehrberger J., Hauff P., Thierauch K.H., Alves F., Wiedenmann B., Scholz A. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J. 2011, 25:3325-3335.
256. Selvaraj S.K., Giri R.K., Perelman N., Johnson C., Malik P., Kalra V.K. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003, 102:1515-1524.
257. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
258. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
259. Sengupta S., Gherardi E., Sellers L.A., Wood J.M., Sasisekharan R., Fan T.P. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2003, 23:69-75.
260. Sennino B., McDonald D.M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 2012, 12:699-709.
261. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
262. Shao Y.Y., Hsu C.H., Cheng A.L. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?. Liver Cancer 2013, 2:93-107.
263. Shaw J.H., Xiang L., Shah A., Yin W., Lloyd P.G. Placenta growth factor expression is regulated by hydrogen peroxide in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2011, 300:C349-C355.
264. Shchors K., Evan G. Tumor angiogenesis: cause or consequence of cancer?. Cancer Res. 2007, 67:7059-7061.
265. Sheen-Chen S.M., Liu Y.W., Eng H.L., Chou F.F. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:715-717.
266. Shi Y.H., Bingle L., Gong L.H., Wang Y.X., Corke K.P., Fang W.G. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007, 39:396-400.
267. Shih S.C., Ju M., Liu N., Smith L.E. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest. 2003, 112:50-57.
268. Shim W.S.N., Ho I.A.W., Wong P.E.H. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 2007, 5:655-665.
269. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6742-6747.
270. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
271. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
272. Stoeltzing O., Ahmad S.A., Liu W., McCarty M.F., Wey J.S., Parikh A.A., Fan F., Reinmuth N., Kawaguchi M., Bucana C.D., Ellis L.M. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 2003, 63:3370-3377.
273. Strasser G.A., Kaminker J.S., Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010, 115:5102-5110.
274. Stratmann A., Risau W., Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 1998, 153:1459-1466.
275. Sundberg C., Kowanetz M., Brown L.F., Detmar M., Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab. Invest. 2002, 82:387-401.
276. Suri C., McClain J., Thurston G., McDonald D.M., Zhou H., Oldmixon E.H., Sato T.N., Yancopoulos G.D. Increased vascularization in mice over expressing angiopoietin-1. Science 1998, 282:468-471.
277. Tammali R., Reddy A.B.M., Srivastava S.K., Ramana K.V. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 2011, 14:209-221.
278. Tarallo V., Vesci L., Capasso O., Esposito M.T., Riccioni T., Pastore L., Orlandi A., Pisano C., De Falco S. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res. 2010, 70:1804-1813.
279. Teunis M.A., Kavelaars A., Voest E., Bakker J.M., Ellenbroek B.A., Cools A.R., Heijnen C.J. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyper reactive dopaminergic system. FASEB J. 2002, 16:1465-1467.
280. Thomas M., Augustin H.G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12:125-137.
281. Thomas M., Felcht M., Kruse K., Kretschmer S., Deppermann C., Biesdorf A., Rohr K., Benest A.V., Fiedler U., Augustin H.G. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J. Biol. Chem. 2010, 285:23842-23849.
282. Thurston G., Daly C. The complex role of angiopoietin-2 in the angiopoietin-Tie signaling pathway. Cold Spring Harb. Perspect. Med. 2012, 2:a006650.
283. Thurston G., Noguera-Troise I., Yancopoulos G.D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 2007, 7:327-331.
284. Thurston G., Wang Q., Baffert F., Rudge J., Papadopoulos N., Jean-Guillaume D., Wiegand S., Yancopoulos G.D., McDonald D.M. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 2005, 132:3317-3326.
285. Tirziu D., Simons M. Angiogenesis in the human heart: gene and cell therapy. Angiogenesis 2005, 8:241-251.
286. Tran H.T., Liu Y., Zurita A.J., Lin Y., Baker-Neblett K.L., Martin A.M., Figlin R.A., Hutson T.E., Sternberg C.N., Amado R.G., Pandite L.N., Heymach J.V. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012, 13:827-837.
287. Tremolada G., Del Turco C., Lattanzio R., Maestroni S., Maestroni A., Bandello F., Zerbini G. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp. Diabetes Res. 2012, 2012:728325.
288. Trujillo A., McGee C., Cogle C.R. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J. Oncol. 2012, 2012:128608.
289. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
290. Uemura A., Ogawa M., Hirashima M., Fujiwara T., Koyama S., Takagi H., Honda Y., Wiegand S.J., Yancopoulos G.D., Nishikawa S. Recombinant angiopoietin-1 restores higher order architecture of growing blood vessels in mice in the absence of mural cells. J. Clin. Invest. 2002, 110:1619-1628.
291. Valenzuela D.M., Griffiths J.A., Rojas J., Aldrich T.H., Jones P.F., Zhou H., McClain J., Copeland N.G., Gilbert D.J., Jenkins N.A., Huang T., Papadopoulos N., Maisonpierre P.C., Davis S., Yancopoulos G.D. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1904-1909.
292. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van Steenkiste C., Tugues S., Rolny C., De Mol M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van Bergen T., Cuervo H., Xiao W.H., Le Henaff C., Buysschaert I., Kharabi Masouleh B., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jiménez W., Noël A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P., Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van Vlierberghe H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
293. Vecchiarelli-Federico L.M., Cervi D., Haeri M., Li Y., Nagy A., Ben-David Y. vascular endothelial growth factor-A positive and negative regulator of tumor growth. Cancer Res. 2010, 70:863-867.
294. Verheul H.M., Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 2007, 7:475-485.
295. Von Tell D., Armulik A., Betsholtz C. Pericytes and vascular stability. Exp. Cell Res. 2006, 312:623-629.
296. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 1993, 268:21513-21518.
297. Weng W.T., Huang S.C., Ma Y.L., Chan H.H., Lin S.W., Wu J.C., Wu C.Y., Wen Z.H., Wang E.M., Wu C.L., Tai M.H. a-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway. Biochim. Biophys. Acta 2014, 1840:1850-1860.
298. Wang Z., Ahmad A., Li Y., Kong D., Azmi A.S., Banerjee S., Sarkar F.H. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim. Biophys. Acta 2010, 1806:122-130.
299. Wehland M., Bauer J., Infanger M., Grimm D. Target-based anti-angiogenic therapy in breast cancer. Curr. Pharm. Des. 2012, 18:4244-4257.
300. Wehland M., Bauer J., Magnusson N.E., Infanger M., Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int. J. Mol. Sci. 2013, 14:9338-9364.
301. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
302. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., Cohen K.S., Scadden D.T., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Shellito P.C., Mino-Kenudson M., Lauwers G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 2005, 23:8136-8139.
303. Xin X., Yang S., Ingle G., Zlot C., Rangell L., Kowalski J., Schwall R., Ferrara N., Gerritsen M.E. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 2001, 158:1111-1120.
304. Xu L., Cochran D.M., Tong R.T., Winkler F., Kashiwagi S., Jain R.K., Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 2006, 66:3971-3977.
305. Xu Y., Liu Y.J., Yu Q. Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res. 2004, 64:6119-6126.
306. Yang J., Wang Q., Qiao C., Lin Z., Li X., Huang Y., Zhou T., Li Y., Shen B., Lv M., Feng J. Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60. Cell. Mol. Immunol. 2014, 10.1038/cmi.2014.6.
307. Yang X., Zhang X.F., Lu X., Jia H.L., Liang L., Dong Q.Z., Ye Q.H., Qin L.X. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 2013, 10.1002/hep.26941.
308. Yonekura H., Sakurai S., Liu X. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. 1999, 274:35172-35178.
309. Yoo S.A., Yoon H.J., Kim H.S., Chae C.B., De Falco S., Cho C.S., Kim W.U. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum. 2009, 60:345-354.
310. You W.K., McDonald D.M. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 2008, 41:833-839.
311. Zhang J., Han C., Zhu H., Song K., Wu T. miR-101 inhibits cholangiocarcinoma angiogenesis vascular endothelial growth factor (VEGF). Am. J. Pathol. 2013, 182:1629-1639. 10.1016/j.ajpath.2013.01.045.
312. Zhang Z.L., Zhang J.F., Yuan Y.F., He Y.M., Liu Q.Y., Mao X.W., Ai Y.B., Liu Z.S. Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Exp. Ther. Med. 2014, 7:543-552.
313. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
314. Zhang Y.W., Su Y., Volpert O.V., Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12718-12723.
315. Zhao J., Yang Q., Yang J., Wang J., Fan L., Wang L. Basic fibroblast growth factor affects the expression of angiogenin and cell proliferation in A375 human melanoma cells. Tumori 2011, 97:95-103.
316. Zhao L., Zhang C., Liao G., Long J. RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model. Cancer Biol. Ther. 2009, 9:1-7.
317. Zagzag D., Hooper A., Friedlander D.R., Chan W., Holash J., Wiegand S.J., Yancopoulos G.D., Grumet M. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 1999, 159:391-400.
318. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., Paoletti I., Barra A., Tucci M., Parise G., Vincenti V., Granger H.J., Viglietto G., Persico M.G. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab. Invest. 1997, 76:517-531.
319. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of. VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex, J. Biol. Chem. 2009, 284(10):6038-6042.
320. Davis S., Papadopoulos N., Aldrich T.H., Maisonpierre P.C., Huang T., Kovac L., Xu A., Leidich R., Radziejewska E., Rafique A., et al. Angio poietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 2003, 10:38-44.
321. Vajkoczy P., Farhadi M., Gaumann A., Heidenreich R., Erber R., Wunder A., Tonn J.C., Menger M.D., Breier G. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest. 2002, 09(6):777-785.
322. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010, 5;102(1):8-18.